Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.15USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$3.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
289,614
52-wk High
$4.86
52-wk Low
$2.40

Select another date:

Mon, Oct 3 2016

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing

BRIEF-AcelRx Pharmaceuticals initiates late-stage study of its painkiller

* Initiates phase 3 study of Zalviso in patients with moderate-to-severe acute post-operative pain Source text for Eikon: Further company coverage:

AcelRx's opioid painkiller succeeds in key study

AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

UPDATE-1-AcelRx's opioid painkiller succeeds in key study

Sept 15 AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial

* Reports positive results for ARX-04 (sufentanil sublingual tablet, 30 mcg), including in elderly patients and patients with organ impairment, in third Phase 3 registration trial, SAP303

BRIEF-Acelrx Pharmaceuticals posts results from phase 3 study of ARX-04

* Acelrx pharmaceuticals presents results from phase 3 study of ARX-04 in the emergency department at the international society for burn injuries

BRIEF-AcelRx Pharmaceuticals says ARX-04 phase 3 trial met primary endpoint

* Overall ARX-04 was well tolerated in study, with 79% of patients reporting no adverse events

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.24

* Acelrx Pharmaceuticals provides corporate update and reports second quarter and six months 2016 financial results

BRIEF-Acelrx enters controlled equity offering sales agreement

* Entered controlled equity offering sales agreement to offer and sell shares of common stock par value $0.001 per share of up to $40 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Select another date: